Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Gossamer Bio, Inc.GOSS · Entity 6928 | Chief Scientific Officer | March 23, 2021 | March 25, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Gossamer Bio, Inc.
Report date March 23, 2021 · Filed March 25, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 206,065 |
Reported balance
After 2021-03-23 transaction · row 1
1 source rowRow 1 · 2021-03-23 · Sale · Disposed 5,491 · Balance 206,065 F1: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Jounce Therapeutics, Inc.
Report date May 03, 2023 · Filed May 04, 2023
Section 16 reporting ended · disclosed 2023-05-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.36 | Direct | 0 |
Reported balance
After 2023-05-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-05-03 · Disposition to issuer · Disposed 31,400 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub, Inc., a direct and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of March 26, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 3, 2023 (the "Effective Time"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.27 | Direct | 0 |
Reported balance
After 2023-05-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-05-03 · Disposition to issuer · Disposed 7,850 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.80 | Direct | 0 |
Reported balance
After 2023-05-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-05-03 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub, Inc., a direct and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of March 26, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 3, 2023 (the "Effective Time").
F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 03, 2023 Filed May 4, 2023 07:45 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $2.80 | Not disclosed |
DisclosureSEC source: 0001640455-23-000114 · wf-form4_168320071989345.xml · derivative · entry 3 Salter-Cid Luisa · CIK 0001766404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. Read SEC document |
| May 03, 2023 Filed May 4, 2023 07:45 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,850 | Not disclosed Strike: $7.27 | Not disclosed |
DisclosureSEC source: 0001640455-23-000114 · wf-form4_168320071989345.xml · derivative · entry 2 Salter-Cid Luisa · CIK 0001766404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,850 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. Read SEC document |
| May 03, 2023 Filed May 4, 2023 07:45 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Disposition to issuerStock Option (Right to Buy) · Derivative | 31,400 | Not disclosed Strike: $12.36 | Not disclosed |
DisclosureSEC source: 0001640455-23-000114 · wf-form4_168320071989345.xml · derivative · entry 1 Salter-Cid Luisa · CIK 0001766404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,400 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub, Inc., a direct and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of March 26, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 3, 2023 (the "Effective Time"). F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 21:08 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001640455-22-000075 · wf-form4_165646491790216.xml · derivative · entry 1 Salter-Cid Luisa · CIK 0001766404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-24 F1 · derivative.exercise_date: The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2023 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 16:50 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | GrantStock Option (Right to Buy) · Derivative | 7,850 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001640455-21-000115 · wf-form4_162439499262324.xml · derivative · entry 1 Salter-Cid Luisa · CIK 0001766404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,850 Underlying: Common Stock · 7,850 shares Expires 2031-06-18 F1 · derivative.exercise_date: The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2022 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 20:13 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | SaleCommon Stock | 5,491 | $9.48 | $52,051.93 |
DisclosureSEC source: 0001728117-21-000033 · wf-form4_161670321781288.xml · nonDerivative · entry 1 Salter-Cid Luisa · CIK 0001766404 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,065 F1 · shares: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:54 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $9.79 | $0.00 |
DisclosureSEC source: 0001728117-21-000025 · wf-form4_161463558108922.xml · derivative · entry 2 Salter-Cid Luisa · CIK 0001766404 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2031-02-25 F3 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on February 25, 2022 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:54 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001728117-21-000025 · wf-form4_161463558108922.xml · nonDerivative · entry 1 Salter-Cid Luisa · CIK 0001766404 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,556 F1 · shares: Represents restricted stock unit award, which will vest in three equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date. F2 · balance_after: Includes 32,641 shares subject to forfeiture, which shares will vest in equal monthly installments as set forth in the restricted stock agreement between the Issuer and Reporting Person so that all of the shares will be released from the forfeiture restriction on November 18, 2021, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Also includes 46,500 restricted stock units granted in February 2020, which shares will vest in three equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 08:10 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | GrantStock Option (Right to Buy) · Derivative | 31,400 | $0.00 Strike: $12.36 | $0.00 |
DisclosureSEC source: 0001640455-21-000037 · wf-form4_161313540118759.xml · derivative · entry 1 Salter-Cid Luisa · CIK 0001766404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,400 Underlying: Common Stock · 31,400 shares Expires 2031-02-10 F1 · derivative.exercise_date: The option was granted on February 10, 2021 and will vest in equal quarterly installments during the twelve quarters following the grant date, subject the to Reporting Person's continued service as a director. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:21 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (right to buy) · Derivative | 71,500 | $0.00 Strike: $14.55 | $0.00 |
DisclosureSEC source: 0001209191-20-010519 · doc4.xml · derivative · entry 2 Salter-Cid Luisa · CIK 0001766404 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,500 Underlying: Common Stock · 71,500 shares Expires 2030-02-14 F3 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on February 14, 2021 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:21 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantCommon Stock | 46,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010519 · doc4.xml · nonDerivative · entry 1 Salter-Cid Luisa · CIK 0001766404 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,556 F1 · shares: Represents restricted stock unit award, which will vest in three equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date. F2 · balance_after: Includes 76,153 shares subject to forfeiture, which shares will vest in equal monthly installments as set forth in the restricted stock agreement between the Issuer and Reporting Person so that all of the shares will be released from the forfeiture restriction on November 18, 2021, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 22:00 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GiftCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-000367 · doc4.xml · nonDerivative · entry 1 Salter-Cid Luisa · CIK 0001766404 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,056 Read SEC document |
| August 29, 2019 Filed Aug 29, 2019 22:26 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | SaleCommon Stock | 26,252 | $20.09 | $527,318.67 |
DisclosureSEC source: 0001209191-19-047753 · doc4.xml · nonDerivative · entry 2 Salter-Cid Luisa · CIK 0001766404 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,056 F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.71 to $20.42 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 97,908 shares subject to forfeiture, which shares will vest in equal monthly installments as set forth in the restricted stock agreement between the Issuer and Reporting Person so that all of the shares will be released from the forfeiture restriction on November 20, 2021, subject to the Reporting Person's continuous service to the Corporation on each such vesting date. The shares are also subject to certain accelerated vesting provisions as set forth in more detail in the employment agreement between the Issuer and the Reporting Person. Read SEC document |
| August 28, 2019 Filed Aug 29, 2019 22:26 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | SaleCommon Stock | 23,748 | $19.65 | $466,724.19 |
DisclosureSEC source: 0001209191-19-047753 · doc4.xml · nonDerivative · entry 1 Salter-Cid Luisa · CIK 0001766404 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,308 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.50 to $19.96 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 97,908 shares subject to forfeiture, which shares will vest in equal monthly installments as set forth in the restricted stock agreement between the Issuer and Reporting Person so that all of the shares will be released from the forfeiture restriction on November 20, 2021, subject to the Reporting Person's continuous service to the Corporation on each such vesting date. The shares are also subject to certain accelerated vesting provisions as set forth in more detail in the employment agreement between the Issuer and the Reporting Person. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 22:54 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $22.10 | $0.00 |
DisclosureSEC source: 0001209191-19-021368 · doc4.xml · derivative · entry 1 Salter-Cid Luisa · CIK 0001766404 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2029-03-25 F1 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on March 25, 2020 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Corporation on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.